Get the Stockscreener App
7.90
1.94%
0.15
Avadel Pharmaceuticals Plc stock is traded at $7.90, with a volume of 2.25M.
It is up +1.94% in the last 24 hours and down -23.38% over the past month.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
See More
Previous Close:
$7.75
Open:
$7.93
24h Volume:
2.25M
Relative Volume:
1.61
Market Cap:
$761.26M
Revenue:
$47.56M
Net Income/Loss:
$-156.83M
P/E Ratio:
-4.3169
EPS:
-1.83
Net Cash Flow:
$-127.98M
1W Performance:
-1.86%
1M Performance:
-23.38%
6M Performance:
-51.23%
1Y Performance:
-47.26%
1-Day Range:
$7.63
$8.025
1-Week Range:
$7.63
$8.74
52-Week Range:
$7.39
$19.09
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Name
Avadel Pharmaceuticals Plc
Sector
Phone
636-449-1830
Address
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Compare AVDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
7.90 | 761.26M | 47.56M | -156.83M | -127.98M | -1.83 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-05-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-05-24 | Reiterated | Needham | Buy |
| Mar-05-24 | Reiterated | Oppenheimer | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Nov-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-28-22 | Resumed | Craig Hallum | Buy |
| May-26-22 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-21-20 | Initiated | SVB Leerink | Outperform |
| Jun-30-20 | Initiated | H.C. Wainwright | Buy |
| Apr-03-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Initiated | Stifel | Buy |
| Feb-26-20 | Initiated | Piper Sandler | Overweight |
| Jan-30-20 | Initiated | Craig Hallum | Buy |
| Jun-14-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-08-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
View All
Avadel Pharmaceuticals Plc Stock (AVDL) Latest News
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Rating of "Buy" by Analysts - MarketBeat
There May Still Be Time to Get in on These 3 Trending Biotechs - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Up Following Insider Buying Activity - MarketBeat
Avadel Pharmaceuticals director Peter Thornton buys shares worth $80,450 By Investing.com - Investing.com Australia
Avadel Pharmaceuticals director Peter Thornton buys shares worth $80,450 - Investing.com India
Insider Buying: Peter Thornton Acquires 10,000 Shares of Avadel Pharmaceuticals PLC - GuruFocus.com
Peter J. Thornton Purchases 10,000 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) Stock - MarketBeat
Avadel Pharmaceuticals director Eric Ende buys $235,218 in shares By Investing.com - Investing.com South Africa
Avadel Pharmaceuticals director Eric Ende buys $235,218 in shares - Investing.com
Avadel Pharmaceuticals (NASDAQ:AVDL) Given New $14.00 Price Target at UBS Group - MarketBeat
What is Lifesci Capital's Forecast for AVDL FY2024 Earnings? - MarketBeat
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook (NASDAQ:AVDL) - Seeking Alpha
Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target Lowered to $13.00 at Piper Sandler - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Earns Buy Rating from HC Wainwright - MarketBeat
Avadel reports strong Q4 growth for narcolepsy drug LUMRYZ By Investing.com - Investing.com Australia
Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target Cut to $19.00 by Analysts at Needham & Company LLC - MarketBeat
Avadel Pharmaceuticals plc Provides Update on Revitalyz Pivotal Study - Marketscreener.com
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ - Benzinga
Avadel announces preliminary Q4 net product revenue of $50 million - MSN
AVDLAvadel Pharmaceuticals plc Ordinary Share Latest Stock News & Market Updates - StockTitan
After-hours movers: NVIDIA, Costco, Penguin Solutions, Avadel Pharma By Investing.com - Investing.com Nigeria
Avadel reports strong Q4 growth for narcolepsy drug LUMRYZ - Investing.com
Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ - TipRanks
Avadel Pharmaceuticals falls as Q4 revenue misses estimates; shares sink 20% - Investing.com Nigeria
Avadel Pharmaceuticals falls as Q4 revenue misses estimates; shares sink 20% By Investing.com - Investing.com South Africa
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch - The Manila Times
Avadel's LUMRYZ Narcolepsy Drug Hits $50M in Q4, Patient Base Surges 275% as Growth Accelerates - StockTitan
Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Report Previe - GuruFocus.com
Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Avadel Pharmaceuticals Grants Stock Options to 12 New Employees in Strategic Talent Expansion - StockTitan
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - The Manila Times
Avadel Pharmaceuticals Schedules Q4 & Full Year 2024 Financial Results Conference Call - StockTitan
Geode Capital Management LLC Has $15.14 Million Stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Stifel Financial Corp Sells 1,452 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $24.43 Consensus Price Target from Analysts - MarketBeat
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Rating of “Buy” by Analysts - Defense World
Fmr LLC Makes New $31,000 Investment in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Purchased by State Street Corp - Defense World
State Street Corp Raises Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - MarketBeat
How the (AVDL) price action is used to our Advantage - Stock Traders Daily
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $484,000 Investment in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Barclays PLC Buys 123,430 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - MarketBeat
C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches - Benzinga
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Purchased by Lord Abbett & CO. LLC - MarketBeat
Avadel Pharmaceuticals Plc Stock (AVDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):